Target
INDICATION
DRUG CANDIDATE
TARGET ID & VALIDATION
DRUG DISCOVERY
IND ENABLING STUDIES
PHASE I
OTOPROTECTION
Prevention of Cisplatin Ototoxicity
DB-020
Target
TARGET ID & VALIDATION
DRUG DISCOVERY
IND ENABLING STUDIES
PHASE I
P1b efficacy & safety in cisplatin patients ongoing
CONGENITAL DEAFNESS
Congenital Deafness
DB-XX2*
Target
TARGET ID & VALIDATION
DRUG DISCOVERY
IND ENABLING STUDIES
PHASE I
Undisclosed
Congenital Deafness
DB-XX3*
Target
TARGET ID & VALIDATION
DRUG DISCOVERY
IND ENABLING STUDIES
PHASE I
DB-XX3* Undisclosed Congenital Deafness
Undisclosed
Congenital Deafness
DB-XX4*
Target
TARGET ID & VALIDATION
DRUG DISCOVERY
IND ENABLING STUDIES
PHASE I
DB-XX4* Undisclosed Congenital Deafness
PREVALENT CONDITIONS
Undisclosed
Age-Related Balance; BVH
DB-XX1*
Target
TARGET ID & VALIDATION
DRUG DISCOVERY
IND ENABLING STUDIES
PHASE I
DB-XX1* Undisclosed Age-Related Balance; BVH
Undisclosed
Tinnitus; Peripheral Neuropathy
DB-XX5*
Target
TARGET ID & VALIDATION
DRUG DISCOVERY
IND ENABLING STUDIES
PHASE I
DB-XX5* Undisclosed Tinnitus; Peripheral Neuropathy
Novel Discovery
Noise & Age-Induced Hearing Loss
Target
TARGET ID & VALIDATION
DRUG DISCOVERY
IND ENABLING STUDIES
PHASE I
Novel Discovery Noise & Age-Induced Hearing Loss

OTOPROTECTION

Target
INDICATION
DRUG CANDIDATE
TARGET ID & VALIDATION
DRUG DISCOVERY
IND ENABLING STUDIES
PHASE I
Prevention of Cisplatin Ototoxicity
DB-020
Target
TARGET ID & VALIDATION
DRUG DISCOVERY
IND ENABLING STUDIES
PHASE I

CONGENITAL DEAFNESS

Target
INDICATION
DRUG CANDIDATE
TARGET ID & VALIDATION
DRUG DISCOVERY
IND ENABLING STUDIES
PHASE I
Congenital Deafness
DB-XX2*
Target
TARGET ID & VALIDATION
DRUG DISCOVERY
IND ENABLING STUDIES
PHASE I
Undisclosed
Congenital Deafness
DB-XX3*
Target
TARGET ID & VALIDATION
DRUG DISCOVERY
IND ENABLING STUDIES
PHASE I
DB-XX3* Undisclosed Congenital Deafness
Undisclosed
Congenital Deafness
DB-XX4*
Target
TARGET ID & VALIDATION
DRUG DISCOVERY
IND ENABLING STUDIES
PHASE I
DB-XX4* Undisclosed Congenital Deafness

PREVALENT CONDITIONS

Target
INDICATION
DRUG CANDIDATE
TARGET ID & VALIDATION
DRUG DISCOVERY
IND ENABLING STUDIES
PHASE I
Undisclosed
Age-Related Balance; BVH
DB-XX1*
Target
TARGET ID & VALIDATION
DRUG DISCOVERY
IND ENABLING STUDIES
PHASE I
DB-XX1* Undisclosed Age-Related Balance; BVH
Undisclosed
Tinnitus; Peripheral Neuropathy
DB-XX5*
Target
TARGET ID & VALIDATION
DRUG DISCOVERY
IND ENABLING STUDIES
PHASE I
DB-XX5* Undisclosed Tinnitus; Peripheral Neuropathy
Novel Discovery
Noise & Age-Induced Hearing Loss
Target
TARGET ID & VALIDATION
DRUG DISCOVERY
IND ENABLING STUDIES
PHASE I
Novel Discovery Noise & Age-Induced Hearing Loss

*Currently included in the Decibel Regeneron collaboration. Decibel retains worldwide development and commercial rights. Regeneron co-funds the development of collaboration programs and receives tiered royalties based on net sales.